What it is
Enalapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) that blocks the conversion of angiotensin I into angiotensin II (a powerful vasoconstrictor). It lowers blood pressure, reduces afterload and reduces left ventricular remodelling.
It is first line in hypertension (especially with comorbidities such as diabetes or heart failure). It has a proven kidney benefit in diabetes. It is very well tolerated, although with some characteristic effects (dry cough).
Mechanism of action
It inhibits:
- Angiotensin-converting enzyme (ACE): it blocks the conversion of Ang I → Ang II
- It reduces systemic and renal vasoconstriction
- It reduces aldosterone synthesis, reducing sodium retention
At the counter
When to recommend it
- Essential hypertension (first line)
- Heart failure with reduced ejection fraction (it reduces mortality)
- Kidney protection in diabetes (it reduces proteinuria)
- Ischaemic heart disease after a heart attack
When not to
- Previous angioedema with an ACE inhibitor
- Severe uncontrolled hyperkalaemia
- Pregnancy (not advised in the first trimester and contraindicated in the second and third) and breastfeeding
- Bilateral renal artery stenosis
Warnings
- Important Angioedema: rare but serious. Swelling of the lips, tongue or throat. Stop immediately and seek urgent care.
- Important Hyperkalaemia: especially with NSAIDs or potassium-sparing diuretics. Monitor potassium.
- Caution Dry cough: common, caused by bradykinin build-up. It is not an allergy; if it is bothersome, the doctor can switch to an ARB.
- Caution Low blood pressure: especially with the first dose. Gradual dose increases are recommended.
Pharmacokinetics
- Absorption
- Around 60% oral absorption, unaffected by food. Enalapril peaks at 1 hour; enalaprilat (the active form) at 3–4 hours.
- Distribution
- Wide distribution. Plasma protein binding of 50–60%. It crosses the placenta.
- Metabolism
- Enalapril is a prodrug: it is converted in the liver into enalaprilat (the active form). Enalaprilat is not absorbed orally (it is very polar).
- Elimination
- Renal elimination of enalaprilat. Half-life of 11 hours.
Enalapril vs losartan (ARB)
| Aspect | Enalapril | Losartan (ARB) |
|---|---|---|
| Mechanism | Blocks ACE | Blocks the Ang II AT1 receptor |
| Blood pressure effect | High | Similar |
| Dry cough | Common | Rare |
| Kidney protection | Very good | Very good (including diabetic nephropathy) |
| First line | Yes | Yes (if the ACE inhibitor causes cough) |
Enalapril is first line. An ARB if the ACE inhibitor causes an intolerable cough.
Self-assessment
Three questions. When you check your answers you will see the explanation for each one.
-
Enalapril is an ACE inhibitor: it blocks the enzyme that converts Ang I into Ang II. ARBs block the receptor (a different mechanism).
-
The cough is a class effect of ACE inhibitors (they block the breakdown of bradykinin), not an allergy. It is common and not dangerous, but if it is bothersome the doctor can switch to an ARB.
-
Enalapril reduces glomerular hyperfiltration and proteinuria in people with diabetes. It protects against progression to kidney failure.
Training content. It does not replace the summary of product characteristics or clinical judgement.